Invention Grant
US08426363B2 Method for reducing a level of LDL-cholesterol by an antibody that specifically binds to PCSK9
有权
通过特异性结合PCSK9的抗体降低LDL-胆固醇水平的方法
- Patent Title: Method for reducing a level of LDL-cholesterol by an antibody that specifically binds to PCSK9
- Patent Title (中): 通过特异性结合PCSK9的抗体降低LDL-胆固醇水平的方法
-
Application No.: US13225265Application Date: 2011-09-02
-
Publication No.: US08426363B2Publication Date: 2013-04-23
- Inventor: Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
- Applicant: Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
- Applicant Address: US CA South San Francisco US NY New York
- Assignee: Rinat Neuroscience Corp.,Pfizer Inc.
- Current Assignee: Rinat Neuroscience Corp.,Pfizer Inc.
- Current Assignee Address: US CA South San Francisco US NY New York
- Agency: Pfizer Inc.
- Main IPC: A61P3/06
- IPC: A61P3/06 ; A61K38/00
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
Public/Granted literature
- US20120014951A1 PCSK9 ANTAGONISTS Public/Granted day:2012-01-19
Information query
